Insider · CIK 0001609284
Nicholas A Saccomano
Files at OKUR (OnKure Therapeutics, Inc.). First filing Apr 8, 2025, latest Sep 23, 2026.
In brief
Nicholas A Saccomano files SEC Form 4 as CEO, president and director at OKUR (OnKure Therapeutics, Inc.). Since Apr 8, 2025, Nicholas A Saccomano has reported 0 open-market buys worth $0 and 7 open-market sells worth $4,263, the latest filed on Sep 23, 2026.
A track record needs three past buys with six months of prices behind them; Nicholas A Saccomano has 0, so none is measured yet.
The newest scored trade: sold $259 of OKUR on Sep 21, 2026, filed Sep 23, 2026, scored 33 (weak). In the last 12 months: 0 buys worth $0 and 4 sells worth $1,252.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
OKUR: OnKure Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | OnKure Therapeutics, Inc. | $259 87 shares | -1% | - | |
| 33Weak | OnKure Therapeutics, Inc. | $378 86 shares | -1% | +122% from low-16% from high | |
| 33Weak | OnKure Therapeutics, Inc. | $357 86 shares | -1% | +117% from low-20% from high | |
| 33Weak | OnKure Therapeutics, Inc. | $258 87 shares | -1% | +62% from low-67% from high | |
| 33Weak | OnKure Therapeutics, Inc. | $231 88 shares | -2% | +43% from low-86% from high | |
| 33Weak | OnKure Therapeutics, Inc. | $210 88 shares | -2% | +32% from low-87% from high | |
| 38Weak | OnKure Therapeutics, Inc. | $2,570 874 shares | -19% | 0% from low-84% from high |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -87 | $2.97 | $259 | 11,160 | 20 d ago |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Aug 11, 2026 |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -2,359 | - | - | 0 | Aug 11, 2026 |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +2,359 | - | - | 2,359 | Aug 11, 2026 |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -1,485 | - | - | 0 | Aug 11, 2026 |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +1,485 | - | - | 1,485 | Aug 11, 2026 |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -8,449 | - | - | 0 | Aug 11, 2026 |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +8,449 | - | - | 8,449 | Aug 11, 2026 |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,898 | - | - | 0 | Aug 11, 2026 |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +16,898 | - | - | 16,898 | Aug 11, 2026 |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -542,232 | - | - | 0 | Aug 11, 2026 |
| Aug 7, 2026 | OKUR OnKure Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +542,232 | - | - | 542,232 | Aug 11, 2026 |
| Jun 22, 2026 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -86 | $4.40 | $378 | 11,247 | Jun 24, 2026 |
| Apr 1, 2026 | OKUR OnKure Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +330,000 | $0.00 | $0 | 330,000 | Apr 3, 2026 |
| Mar 23, 2026 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -86 | $4.16 | $357 | 7,333 | Mar 24, 2026 |
| Dec 22, 2025 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -87 | $2.97 | $258 | 7,419 | Dec 23, 2025 |
| Sep 22, 2025 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -88 | $2.62 | $231 | 3,506 | Sep 24, 2025 |
| Jun 23, 2025 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -88 | $2.38 | $210 | 3,594 | Jun 25, 2025 |
| Apr 4, 2025 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -358 | $3.33 | $1,191 | 4,198 | Apr 8, 2025 |
| Apr 7, 2025 | OKUR OnKure Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -516 | $2.67 | $1,378 | 3,682 | Apr 8, 2025 |
Questions about Nicholas A Saccomano
Answered from the filings on this page, as of the latest one.
Is Nicholas A Saccomano buying or selling?
In the last 12 months Nicholas A Saccomano reported 0 open-market buys worth $0 and 4 open-market sells worth $1,252 on SEC Form 4; the latest was sold $259 of OKUR on Sep 21, 2026. Grants, option exercises and tax withholding are not counted.
How did Nicholas A Saccomano's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Nicholas A Saccomano has 0.
Where does Nicholas A Saccomano file Form 4?
Nicholas A Saccomano has filed Form 4 at OKUR (OnKure Therapeutics, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.